Pfizer Q4 Revenue Drops 1.1% to $17.56B, $9.8B Returned
Pfizer reported Q4 2025 revenue of $17.56 billion, a 1.1% decline year-over-year, and full-year revenue of $62.6 billion, while adjusted gross margins expanded to 76%. Pfizer beat estimates and returned $9.8 billion to shareholders, outlining 2026 priorities to leverage Seagen, Metsera and Biohaven acquisitions, advance obesity drugs and expand AI.
1. Q4 2025 Results
Pfizer reported Q4 2025 revenue of $17.56 billion, down 1.1% year-over-year, and full-year revenue of $62.6 billion, reflecting a 2% operational decline. Excluding COVID-19 products, operational revenue grew 6%, and adjusted gross margin expanded to 76%, driven by cost optimization and product mix.
2. Shareholder Returns
The company returned $9.8 billion to shareholders through dividends, underscoring its cash generation strength and commitment to capital allocation. This distribution represented a significant portion of free cash flow for the year.
3. 2026 Strategic Priorities
The CEO outlined targets to fully leverage recent acquisitions such as Seagen, Metsera and Biohaven, accelerate development of the obesity pipeline with the VESPER-3 study of MET-097i, and expand artificial intelligence applications across research and operations.
4. Patent Cliff and Pipeline Offsets
Facing a 2026–2030 patent cliff that threatens key blockbusters, Pfizer is banking on newly launched and acquired drugs to sustain growth. The company emphasized advancing candidates across oncology, primary care and specialty areas to offset revenue declines from expiring patents.